Synta Pharmaceuticals Corp. Earnings Conference Call (Q1 2014) Today's Calls 
Visit the TF Network Sites
Visit the TF Network Sites
· Corporate IR Center
· Institutional Investor Center
· Individual Investor Center
Download Plug-In
Real Player 8 Basic
Windows Media Player
Other Conference Calls
Other May 8 Calls
Today's Calls
Call Details
Synta Pharmaceuticals Corp. Earnings Conference Call (Q1 2014)
Scheduled to start Thu, May 8, 2014, 10:00 am Eastern

-- this event is ongoing now--
Listen to the ongoing live event audio stream

About Synta Pharmaceuticals Corp (NasdaqGM:SNTA)Other Calls 
Synta Pharmaceuticals Corp., a biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule drugs for treating severe medical conditions, including cancer and chronic inflammatory diseases. The company has two drug candidates in clinical trials for treating multiple types of cancer and various drug candidates in the preclinical stage of development. Its lead drug candidate includes ganetespib, an Hsp90 inhibitor, which is in Phase III clinical trial for the treatment of non-small cell lung cancer; in Phase II clinical trial for patients with hormone receptor positive metastatic breast cancer; in Phase I clinical trial for the treatment of HER2 positive patients with metastatic breast cancer; in Phase II/III clinical trial for the treatment of patients with acute myeloid leukemia and myelodysplastic syndrome; and in Phase I/II trial of paclitaxel in combination with ganetespib in patients with platinum-resistant ovarian cancer. The company’s product pipeline also comprises Hsp90-inhibitor Drug Conjugate, a novel, proprietary small molecule cancer drug development program; and Elesclomol, a mitochondria-targeting agent that is in Phase 2 clinical trial for ovarian cancer. Its product pipeline in preclinical development stage for inflammatory diseases includes CRACM ion channel inhibitors for rheumatoid arthritis, asthma, chronic obstructive pulmonary disease, allergy, transplant rejection, and other autoimmune diseases and inflammatory conditions; and IL-12/23 inhibitors for inflammatory and autoimmune diseases. Synta Pharmaceuticals Corp. was incorporated in 2000 and is based in Lexington, Massachusetts.


More Info: Quote | Profile | Reports | Research | Insider | Financials | Analyst Ratings


Copyright © 2014 Yahoo! Inc. All Rights Reserved. Privacy Policy - Terms of Service
Copyright © 2014 FirstCall Events. Historical chart data provided by Commodity Systems, Inc. (CSI). Company profile information presented on this page is Copyright Capital IQ. Data and information is provided for informational purposes only, and is not intended for trading purposes. Neither Yahoo nor any of its data or content providers (such as Capital IQ, CSI, etc.) shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon.